Transaction in Own Shares

Summary by AI BETAClose X

GSK PLC announced on 06 November 2025 that it purchased 170,000 of its ordinary shares of 31¼ pence each on 05 November 2025, as part of its existing buyback programme. The shares were acquired at prices ranging from 1,779.00p to 1,798.00p, with a volume-weighted average price of 1,789.04p, and will be held as Treasury shares. Since the programme commenced on 30 September 2025, the company has bought back 7,819,000 ordinary shares. Following this transaction, GSK now holds 255,283,844 ordinary shares in treasury, with 4,060,139,755 ordinary shares remaining in issue, representing 6.29 per cent of

Disclaimer*

GSK PLC
06 November 2025
 

 

Transaction in own shares

 

GSK plc (the "Company") announces today acting through BNP Paribas SA (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

 

Date of purchase:

05 November 2025

Aggregate number of ordinary shares of 31¼ pence each purchased:

170,000

Lowest price paid per share (GBp):

1,779.00p

Highest price paid per share (GBp):

1,798.00p

Volume-weighted average price paid per share (GBp):

1,789.04p

 

The purchased shares will be held as Treasury shares.

                                                                                                                          

Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 7,819,000 ordinary shares.

 

Following the above purchase, the Company will hold 255,283,844 ordinary shares in treasury and have 4,060,139,755 ordinary shares in issue (excluding Treasury shares).

 

The total number of voting rights in the Company is 4,060,139,755. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.29 per cent.

 

The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.

 

Schedule of Purchases

Shares purchased:   GSK plc (ISIN: GB00BN7SWP63)

Date of purchases:   05 November 2025

Investment firm:       BNP Paribas SA

Aggregated information per trading venue:

 

Individual transactions:

 

 

GSK enquiries




Media:

Tim Foley

+44 (0) 20 8047 5502

(London)


Kathleen Quinn

+1 202 603 5003

(Washington DC)



 


Investor Relations:

Constantin Fest

+44 (0) 7831 826525

(London)


James Dodwell

+44 (0) 20 8047 2406

(London)


Mick Readey

+44 (0) 7990 339653

(London)


Steph Mountifield

+44 (0) 7796 707505

(London)


Sam Piper

+44 (0) 7824 525779

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)


Frannie DeFranco

+1 215 751 3126

(Philadelphia)

 

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q3 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today